Trump-Pfizer Deal Plans Major US Drug Price Cuts, $70B Investment

President Donald Trump announced a landmark agreement with Pfizer, called TrumpRx, aiming to lower prescription drug prices significantly in the US by allowing direct-to-consumer purchases of Pfizer's branded medications at steep discounts. FDA Commissioner Marty Makary praised the move as historic, highlighting that it will reduce costs for Medicaid patients and specialty drugs, which often cause financial hardship for families. The deal includes Pfizer offering all medications to Medicaid at most favored nations prices, discounted popular medications for all consumers, and a $70 billion investment to boost domestic drug manufacturing. Pfizer CEO Albert Bourla emphasized that American patients are the primary beneficiaries of this agreement, which aims to bring fairness and transparency to drug pricing. The Trump administration's approach challenges traditional pharmaceutical pricing models, potentially inspiring other companies to follow suit and easing the burden on American healthcare costs. This initiative represents a bold attempt to reform the US pharmaceutical market while ensuring other countries contribute fairly to the cost of innovation.